Suguru Yamada

19PUBLICATIONS
31CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosisCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Aug 07, 2026
Redefining biologically borderline resectable pancreatic cancer: a data-driven reassessment of CA19-9 cutoff and a preoperative lymph node metastasis prediction model.

|Jun 29, 2026
Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Controlled Trial (NUPAT-01).

|Nov 06, 2025
Prognostic discrepancies between surgery-first and neoadjuvant-treated resected pancreatic cancer in the same pathological stage.

Suguru Yamada, Kenji Oshima, Kosuke Nomoto

|Jul 11, 2024
Reappraisal of the current resectability criteria and optimal treatment strategies for pancreatic cancer.

Suguru Yamada, Kenji Oshima, Kosuke Nomoto

|Jan 16, 2023
Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dual-center study.

Takamichi Igarashi, Suguru Yamada, Yui Hoshino

|Jul 01, 2022
The malignant potential of pancreatic intraductal papillary mucinous neoplasm is reflected in expression levels of fucosylated glycans in α1 -acid glycoprotein.

Norio Kubo, Shin Yazawa, Takehiko Yokobori

Pageof 4

Frequent Collaborators

6 joint publications

Yasuhiro Kodera

5 joint publications

Sohei Satoi

5 joint publications

Tsutomu Fujii

4 joint publications

Fuminori Sonohara